Harnessing Tyrosine Metabolism To Combat Respiratory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$866,467.00
Summary
Cross-talk between our immune system and the microbiome is central to health and disease. In particular, the gut microbiome has wide-ranging effects throughout the body, in part through the production of metabolites with immunomodulatory activity. We have discovered a novel subset of microbial metabolites which can protect mice against allergic airway inflammation, a model of asthma. We now aim to discovery how these metabolites work with a view towards developing them as therapeutics.
Flaviviruses Must Come Of Age: Design Of Stable, Mature Particles By Structural Vaccinology
Funder
National Health and Medical Research Council
Funding Amount
$1,149,487.00
Summary
We have established a powerful toolset combining advanced structural biology and rapid virus engineering that allows us investigate the assembly of flaviviruses in novel ways. This project will integrate these approaches to investigate the role of new ligands that we have identified in the structure of medically-relevant flaviviruses including dengue virus and delineate a novel maturation path for flaviviruses, which will be used to design safer and more effective flavivirus vaccines.
Targeting MiRNA Biogenesis To Treat Herpes Simplex Virus Latency
Funder
National Health and Medical Research Council
Funding Amount
$800,085.00
Summary
Herpes simplex virus (HSV) causes cold sores in most infected people, but can also cause blindness and fatal brain infections. The biggest problem with HSV is that it never completely goes away - the virus hides in a part of the nervous system and can come out to cause disease over and over again. We have recently discovered a gene in people that the virus needs to maintain itself in this hidden state. In this project we will use this exciting discovery to work towards a cure for HSV.
THE IMMUNOLOGICAL LEGACY OF OBESITY ON VIRAL PATHOGENESIS
Funder
National Health and Medical Research Council
Funding Amount
$652,275.00
Summary
Obesity is a key risk factor for severe viral infections. Our preliminary data suggest that in mice this susceptibility is not reduced by weight loss. In this grant we will investigate a) the mechanisms driving the legacy effect of obesity on antiviral immunity b) whether or not we can reverse this legacy effect by treatment with the drug MCC950 and c) the antiviral response of overweight children and adults who have and haven't recently lost weight.
Development Of An Intracellular Tau-specific Antibody Therapeutic For The Treatment Of Alzheimer's Disease
Funder
National Health and Medical Research Council
Funding Amount
$410,378.00
Summary
The protein, tau, is a promising therapeutic target for the treatment of Alzheimer's disease and related dementia's. Targeting tau is a challenge, however, as it is mostly localised within brain cells and a therapeutic must therefore be able to cross multiple barriers to engage and neutralise tau. This project overcomes this hurdle by using virus' to deliver a tau-specific antibody gene across the multiple barriers where it can be produced by brain cells and target intracellular tau.
Oleoyl-ACP-hydrolase As An Early Predictive Biomarker For Severe And Fatal Influenza
Funder
National Health and Medical Research Council
Funding Amount
$866,807.00
Summary
Millions are hospitalized with severe influenza disease and ~500K die annually but the underlying mechanisms that drive disease are still not fully understood. We have identified a key role for an enzyme involved in fatty acid metabolism, which is profoundly elevated in patients who succumb to influenza and is thus a predictor for fatal outcomes. This research aims to investigate how this enzyme affects infection and impairs immune responses to drive severe respiratory viral disease.
Hepatitis B is a leading cause of cirrhosis and liver cancer. Treatments for hepatitis B control the virus, but do not cure it, so people stay on treatment for many years. We have identified an exciting new treatment approach by targeting a gene that controls liver metabolism, called TM6SF2. We will target this gene to develop a cure for hepatitis B.